Loading
Nautilus Biotechnology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Patel Sujal M, was filed 04 Mar 2026.
Nautilus Biotechnology, Inc.: what insiders have been doing
Nautilus Biotechnology, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 4 filings signed by 3 insiders.
Open-market activity splits into 2 purchases totalling €61k and 2 sales totalling €10.1M; 2 insiders sit on the buying side and 1 insider on the selling side. On balance, insiders were net sellers of €10.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 1 senior executive and 1 chief executive. The largest single trade was a sale of €9.3M by AH Equity Partners Bio II, L.L.C., published on 4 June 2026, equal to 10.1% of the market capitalisation.
With 4 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 29 purchases and 2 sales.
The last purchase on record was published on 4 March 2026, which is 228 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
36
Thresholds
n/a
Buy Volume
€8M
29 ops. · all time
Sell Volume
€10M
2 ops. · all time
Who traded when
BuySaleSujal M. Patel3 buys
AH Equity Partners Bio II, L.L.C.2 sales
Anna Mowry1 buy
Kentaro Suzuki1 buy
Matthew B. Murphy1 buy
Parag Mallick1 buy
Since the insiders bought
- +5.7%Entry US$2.44 · Close at T+90 US$2.58
- +30.1%Entry US$1.66 · Close at T+90 US$2.16
- +32.4%Entry US$0.70 · Close at T+365 US$0.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Nautilus Biotechnology, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$3.83.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.45
Analyst consensus
3 analystsStrong buy
US$3.50Target US$3.83(+164%)US$4.00
Income statement
EBITDA-US$60.4M
Net income-US$59M0.0% margin
Valuation
P/Book1.4x
Beta0.87
Balance sheet & cash
Market capUS$184.3M
Total debtUS$30M
Free Cash Flow-US$52M
Debt / Equity21%
Profitability & ownership
ROE-36.2%
ROA-20.8%
% insiders32.0%
% institutions43.0%
Last declaration on 4 June 2026
Declarations36 total
4,615,974 shares@ US$2.3510.07% mcap92.3% of flowCommon StockSEC:0001231919-26-000599:0
384,026 shares@ US$2.350.84% mcap7.7% of flowCommon StockSEC:0001231919-26-000599:1
25,000 shares@ US$2.60954.2% of flowCommon StockSEC:0001378830-26-000003:0
Canonical exit: 2 Jun 2026 (T+90)
4,000 shares@ US$1.49100.0% of flowCommon StockSEC:0002037191-25-000004:0
Canonical exit: 4 Feb 2026 (T+90)
116,500 shares@ US$0.67425.0% of flowCommon StockSEC:0001378830-25-000003:0
Canonical exit: 4 Dec 2025 (T+90)
20,000 shares@ US$0.642913.5% of flowCommon StockSEC:0001865778-25-000003:0
Canonical exit: 3 Dec 2025 (T+90)
15,000 shares@ US$0.76594.2% of flowCommon StockSEC:0001808805-25-000051:0
Canonical exit: 27 Aug 2025 (T+90)
12,000 shares@ US$0.7323100.0% of flowCommon StockSEC:0001808805-25-000049:0
Canonical exit: 6 Aug 2025 (T+90)
53,300 shares@ US$0.99493.6% of flowCommon StockSEC:0001808805-25-000034:0
Canonical exit: 17 Jun 2025 (T+90)
47,031 shares@ US$0.4657.4% of flowCommon StockSEC:0001808805-24-000067:0
35,000 shares@ US$0.4642.6% of flowCommon StockSEC:0001808805-24-000065:0
2,430 shares@ US$2.98850.5% of flowCommon StockSEC:0001808805-24-000026:0
Canonical exit: 6 Jun 2024 (T+90)
7,405 shares@ US$2.64641.3% of flowCommon StockSEC:0001628280-24-009754:0
Canonical exit: 3 Jun 2024 (T+90)
10,000 shares@ US$2.02519.3% of flowCommon StockSEC:0001808805-22-000101:0
Canonical exit: 25 Dec 2022 (T+90)
30,000 shares@ US$2.0255100.0% of flowCommon StockSEC:0001808805-22-000099:0
Canonical exit: 22 Dec 2022 (T+90)
40,000 shares@ US$2.193880.7% of flowCommon StockSEC:0001808805-22-000097:0
Canonical exit: 14 Dec 2022 (T+90)
17,500 shares@ US$2.298216.6% of flowCommon StockSEC:0001808805-22-000095:0
Canonical exit: 17 Nov 2022 (T+90)
2,500 shares@ US$2.858.4% of flowCommon StockSEC:0001808805-22-000093:0
Canonical exit: 10 Nov 2022 (T+90)
41,654 shares@ US$2.92048.8% of flowCommon StockSEC:0001808805-22-000089:0
Canonical exit: 3 Nov 2022 (T+90)
5,500 shares@ US$2.74990.015% mcap5.9% of flowCommon StockSEC:0001808805-22-000075:0
Canonical exit: 25 Sept 2022 (T+90)
10,000 shares@ US$3.2838.7% of flowCommon StockSEC:0001808805-22-000056:0
50,000 shares@ US$3.9614.0% of flowCommon StockSEC:0001808805-22-000054:0
Canonical exit: 7 Aug 2022 (T+90)
50,000 shares@ US$3.597812.1% of flowCommon StockSEC:0001808805-22-000026:0
Canonical exit: 1 Jun 2022 (T+90)
210,000 shares0Common StockSEC:0001808805-21-000031:0
200,000 shares@ US$5.3694.2% of flowCommon StockSEC:0000899243-21-047751:0
Canonical exit: 8 Mar 2022 (T+90)
25 of 36 declarations
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ in the United States under the ticker NAUT. For French-speaking investors, this is best viewed as a high-risk, high-science platform story rather than a mature tools or diagnostics business. The company is developing a single-molecule proteome analysis platform designed to quantify and unlock the complexity of the proteome, with the long-term goal of establishing a new gold standard in proteomics and biomedical research. Nautilus was founded in 2016, is incorporated in Delaware, and became a public company on June 10, 2021 through a combination with a SPAC. Its corporate headquarters are in Seattle, Washington, while its research and development headquarters are in San Carlos, California. ([investors.nautilus.bio](https://investors.nautilus.bio/investor-resources/faqs/?utm_source=openai))
From an industry perspective, Nautilus operates in the emerging proteomics instrumentation and analytical technology space, where competition is shaped by technical sensitivity, workflow robustness, reproducibility, and the ability to generate biologically meaningful insights from highly complex samples. The company is still in a development and validation phase rather than a fully commercial stage. Its future commercial offering is centered on the Voyager platform, alongside proprietary methods such as Iterative Mapping, which Nautilus uses to demonstrate performance and scientific relevance in research applications. Recent work has included assays around Tau proteoforms, highlighting potential relevance to neurodegeneration, oncology, and broader translational research. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai))
Read moreShow less
In competitive terms, Nautilus is trying to differentiate itself from conventional proteomics approaches by delivering a much deeper, single-molecule view of proteins and proteoforms. That positions the company as a technology platform with potentially meaningful upside if adoption materializes in pharmaceutical R&D, academic research, and biomarker discovery. At the same time, the investment case remains execution-sensitive: scientific promise must still translate into product reliability, customer uptake, and eventual revenue generation. The company has said it is making measurable progress toward commercialization, including an expanded Iterative Mapping Early Access Program and a first customer in an NIH-funded cancer study at Baylor College of Medicine. It also appointed an experienced global sales leader in 2026 to support early customer expansion and future platform adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai))
Geographically, Nautilus remains primarily U.S.-based, with headquarters in Seattle and R&D in the San Francisco Bay Area, but its addressable market is global because proteomics is strategically important to pharmaceutical companies, academic labs, and life-science innovators worldwide. Recent highlights include the release of first-quarter 2026 results, continued progress in sample processing and platform validation, and a deeper push toward commercialization. For investors in Europe, NAUT on NASDAQ should therefore be understood as a United States-listed exposure to a next-generation life-science platform with meaningful long-term optionality, but still at a pre-commercial stage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/exhibit991-q1268xkearnings.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
